Contrasting Equillium (NASDAQ:EQ) and Oncobiologics (NASDAQ:OTLK)

Equillium (NASDAQ:EQ) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Insider & Institutional Ownership

27.1% of Equillium shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 17.8% of Equillium shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Equillium and Oncobiologics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10 million	2.04	-$22.40 million	($0.20)	-6.60
Oncobiologics	$1.35 million	79.36	-$62.42 million	($0.77)	-0.57

Equillium has higher revenue and earnings than Oncobiologics. Equillium is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Equillium and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Oncobiologics	N/A	N/A	-254.82%

Analyst Recommendations

This is a summary of current recommendations and price targets for Equillium and Oncobiologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1	1	7	2	2.91
Oncobiologics	1	2	2	0	2.20

Equillium presently has a consensus target price of $7.57, indicating a potential upside of 473.59%. Oncobiologics has a consensus target price of $5.20, indicating a potential upside of 1,081.55%. Given Oncobiologics’ higher probable upside, analysts plainly believe Oncobiologics is more favorable than Equillium.

Risk & Volatility

Equillium has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

Summary

Equillium beats Oncobiologics on 10 of the 13 factors compared between the two stocks.

About Equillium

Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company seeks to address immune-system dysregulation by developing treatments that selectively modulate immune-cell activity rather than broadly suppressing the immune system. Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, a protein involved in the activation and trafficking of certain T cells. The company has evaluated itolizumab in conditions including acute graft-versus-host disease and lupus nephritis.

About Oncobiologics

Oncobiologics, now known as Outlook Therapeutics, Inc. (NASDAQ: OTLK), is a biopharmaceutical company focused on developing and commercializing ophthalmic therapies for retinal diseases. The company was established as Oncobiologics and later changed its name to Outlook Therapeutics to reflect its emphasis on eye-care products. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab designed for intravitreal use. The therapy has been studied for vascular retinal conditions, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.